Is Palantir a Good Stock to Buy?
Palantir Technologies (PLTR) stock soared to its highest level in…
Sell
30
HCM Quote, Financials, Valuation and Earnings
Last price:
$15.01
Seasonality move
:
1.65%
Day range:
$14.79 - $15.71
52-week range:
$12.84 - $21.92
Dividend yield:
0%
P/E ratio:
74.95x
P/S ratio:
4.15x
P/B ratio:
3.37x
Volume:
166.9K
Avg. volume:
89K
1-year change:
-13.2%
Market cap:
$2.6B
Revenue:
$630.2M
EPS (TTM):
$0.20
Analysts' Opinion
-
Consensus RatingHUTCHMED (China) has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $26.43, HUTCHMED (China) has an estimated upside of 76.32% from its current price of $14.99.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $18.00 representing -20.08% downside risk from its current price of $14.99.
Fair Value
-
According to the consensus of 12 analysts, HUTCHMED (China) has 76.32% upside to fair value with a price target of $26.43 per share.
HCM vs. S&P 500
-
Over the past 5 trading days, HUTCHMED (China) has underperformed the S&P 500 by -4.94% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
HUTCHMED (China) does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
HUTCHMED (China) has grown year-over-year revenues for 3 quarters straight. In the most recent quarter HUTCHMED (China) reported revenues of --.
Earnings Growth
-
HUTCHMED (China) has grown year-over-year earnings for 0 quarters straight. In the most recent quarter HUTCHMED (China) reported earnings per share of --.
Enterprise value:
1.8B
EV / Invested capital:
2.13x
Price / LTM sales:
4.15x
EV / EBIT:
1,032.05x
EV / Revenue:
2.89x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-104.47x
Price / Operating cash flow:
17.47x
Enterprise value / EBITDA:
129.13x
Gross Profit (TTM):
$281.3M
Return On Assets:
2.97%
Net Income Margin (TTM):
5.99%
Return On Equity:
4.99%
Return On Invested Capital:
4.51%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Income Statement | ||||||
| Revenue | $204.4M | $209M | $264.1M | $55.2M | $75.8M | |
| Gross Profit | -- | -- | -- | $12.9M | $17.5M | |
| Operating Income | -- | -- | -- | -$45.7M | -$80.5M | |
| EBITDA | -- | -- | -- | -$45.7M | -$80.5M | |
| Diluted EPS | -- | -- | -- | -$0.25 | -$0.40 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $839.9M | $1.1B | $1.1B | |
| Total Assets | -- | -- | $1B | $1.3B | $1.3B | |
| Current Liabilities | -- | -- | $353.9M | $403M | $376.6M | |
| Total Liabilities | -- | -- | $392.6M | $536.4M | $502.3M | |
| Total Equity | -- | -- | $636.9M | $743.4M | $771.9M | |
| Total Debt | -- | -- | $18.1M | $79.3M | $82.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$48.6M | -$58.4M | -$99.7M | -$26.6M | -$49M | |
| Cash From Investing | -- | -- | -- | -$41.3M | -$315.9M | |
| Cash From Financing | -- | -- | -- | -$14.4M | $605.1M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
HCM
Sector
Market Cap
$2.6B
$39.2M
Price % of 52-Week High
68.39%
45.93%
Dividend Yield
0%
0%
Shareholder Yield
0.86%
-0.81%
1-Year Price Total Return
-13.2%
-38.63%
Beta (5-Year)
0.772
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$15.49
200-day SMA
Sell
Level
$17.14
Bollinger Bands (100)
Sell
Level
13.96 - 17.78
Chaikin Money Flow
Buy
Level
21.2M
20-day SMA
Sell
Level
$15.90
Relative Strength Index (RSI14)
Sell
Level
46.80
ADX Line
Sell
Level
16.6
Williams %R
Buy
Level
-82.6667
50-day SMA
Buy
Level
$14.74
MACD (12, 26)
Buy
Level
0.21
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
15.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.1763)
Buy
CA Score
(Annual)
Level (0.1183)
Sell
Beneish M-Score
(Annual)
Level (-1.6283)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-0.0587)
Buy
Piotroski F Score
(Annual)
Level (4)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Stock Forecast FAQ
In the current month, HCM has received 10 Buy ratings 2 Hold ratings, and 0 Sell ratings. The HCM average analyst price target in the past 3 months is $26.43.
-
Where Will HUTCHMED (China) Stock Be In 1 Year?
According to analysts, the consensus estimate is that HUTCHMED (China) share price will rise to $26.43 per share over the next 12 months.
-
What Do Analysts Say About HUTCHMED (China)?
Analysts are divided on their view about HUTCHMED (China) share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that HUTCHMED (China) is a Sell and believe this share price will drop from its current level to $18.00.
-
What Is HUTCHMED (China)'s Price Target?
The price target for HUTCHMED (China) over the next 1-year time period is forecast to be $26.43 according to 12 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is HCM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for HUTCHMED (China) is a Buy. 10 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of HCM?
You can purchase shares of HUTCHMED (China) via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase HUTCHMED (China) shares.
-
What Is The HUTCHMED (China) Share Price Today?
HUTCHMED (China) was last trading at $15.01 per share. This represents the most recent stock quote for HUTCHMED (China). Yesterday, HUTCHMED (China) closed at $14.99 per share.
-
How To Buy HUTCHMED (China) Stock Online?
In order to purchase HUTCHMED (China) stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
